5 Insightful Analyst Questions From Bio-Techne's Q4 Earnings Call

Bio-Techne’s fourth quarter was defined by flat revenue performance, yet the company exceeded Wall Street’s expectations on both top and bottom lines, prompting a positive market response. Management attributed this to continued strength from large pharmaceutical customers and sequential improvement in most product categories, offset by temporary headwinds in cell therapy orders due to recent FDA Fast Track designations. CEO Kim Kelderman highlighted that core reagents, proteomic analysis instruments, and diagnostic kits all showed modest sequential growth, while the company’s profitability benefited from disciplined productivity and cost management initiatives. Notably, operating margins expanded year over year, reflecting the company’s ongoing focus on efficiency.

Is now the time to buy TECH? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Bio-Techne’s Q4 Earnings Call

• Matthew Richard Larew (William Blair) asked about the cadence of underlying business growth after removing cell therapy customer impacts. CFO James Hippel confirmed that mid-single-digit growth is expected as headwinds moderate.
• Daniel Leonard (UBS) pressed on gross margin trends and the drivers of improvement. Hippel explained that margin recovery would be led by a gradual shift toward higher-margin products and a more favorable customer mix.
• Puneet Souda (Leerink Partners) inquired about the timing of biotech funding improvements translating into revenue. CEO Kim Kelderman projected a six-month lag, with faster recovery in reagents and a longer runway for capital equipment.
• Patrick Donnelly (Citigroup) questioned normalization in cell therapy and the impact of order timing from large customers. Kelderman outlined that as headwinds dissipate, cell therapy growth of around 30% should resume.
• Steven McLaurin Etoch (Stephens Inc.) sought detail on organoid revenue and M&A strategy. Kelderman highlighted a $50 million run rate for organoid products and reaffirmed M&A as a strategic priority, especially in antibodies and cell therapy.

Catalysts in Upcoming Quarters

In the coming quarters, our team will watch (1) the pace of recovery in biotech and academic research spending, (2) the return of normalized cell therapy reagent demand as the temporary order headwinds subside, and (3) continued momentum in the Asia-Pacific region, especially China. Positive developments in product adoption, margin expansion, and clarity on M&A activity will also be key milestones for tracking execution.

Bio-Techne currently trades at $64.85, in line with $64.63 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.